Neurology

Your Article Summary

See Latest Articles

Safety/Tolerability and Efficacy of Rivastigmine in Taiwanese Patients with Alzheimer's Disease: A Prospective Post-Marketing Surveillance Study
Clinical Drug Investigation, 10/14/09

Chiu PY et al. – Based on the results of this study, rivastigmine administered usually at a dose of 3–6 mg twice daily was found to be well tolerated. Although the rate of adverse events was high, the majority of these symptoms were mild in severity and short in duration. This study also demonstrated the efficacy of rivastigmine in at least stabilizing the symptoms of Alzheimer's disease.

Today in Dementia...keeping you current

Receive free subspecialty "5-minute updates" via email

Memantine versus donepezil in mild to moderate Alzheimer's disease: a randomized trial with magnetic resonance spectroscopy
European Journal of Neurology, 11/02/09

Safety and Tolerability of Donepezil, Rivastigmine and Galantamine for Patients with Alzheimer's Disease: Systematic Review of the 'Real-World' Evidence
Dementia and Geriatric Cognitive Disorders, 11/09/09

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
Neurology, 11/20/09

See All of Dementia

Today in Neuro/Psych pharmacology...keeping you current

Receive free subspecialty "5-minute updates" via email

Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents
JAMA, 10/29/09

Outcome of intracerebral haemorrhage patients pre-treated with statins
European Journal of Neurology, 11/17/09

Escitalopram and Venlafaxine for the Prophylaxis of Migraine Headache Without Mood Disorders
Clinical Neuropharmacology, 10/02/09

See All of Neuro/Psych pharmacology